Genmab, Bolt Biotherapeutics, and Toray are advancing multiple development candidates, with collaborations with Toray progressing and a Phase 1 study underway in Australia.
1 report, 1 independent
Updated Aug 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Genmab, Bolt Biotherapeutics, and Toray are advancing multiple development candidates, with collaborations with Toray progressing and a Phase 1 study underway in Australia.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Coverage
Newest first; wire copies grouped- GlobeNewswireBolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 m